MX2024000321A - Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno. - Google Patents
Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno.Info
- Publication number
- MX2024000321A MX2024000321A MX2024000321A MX2024000321A MX2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- antibodies
- utilization
- antibody responses
- epitopes
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 230000005875 antibody response Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen métodos y composiciones para dirigir una respuesta de anticuerpos en un sujeto lejos de uno o más primeros epítopos de un antígeno (por ejemplo, epítopos inmunodominantes de un antígeno de vacuna) y hacia uno o más segundos epítopos del antígeno mediante la administración de uno o más anticuerpos que se dirigen a uno o más primeros epítopos del antígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163218486P | 2021-07-05 | 2021-07-05 | |
PCT/US2022/035968 WO2023283134A1 (en) | 2021-07-05 | 2022-07-01 | Utilization of antibodies to shape antibody responses to an antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2024000321A true MX2024000321A (es) | 2024-01-25 |
Family
ID=82839285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2024000321A MX2024000321A (es) | 2021-07-05 | 2022-07-01 | Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4367134A1 (es) |
JP (1) | JP2024527344A (es) |
KR (1) | KR20240042267A (es) |
CN (1) | CN118076631A (es) |
AU (1) | AU2022307659A1 (es) |
CA (1) | CA3226042A1 (es) |
IL (1) | IL309730A (es) |
MX (1) | MX2024000321A (es) |
WO (1) | WO2023283134A1 (es) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US166A (en) | 1837-04-17 | Standing press | ||
US419A (en) | 1837-10-06 | Machine fob boring and mortising wheel-hubs and other articles | ||
US5789A (en) | 1848-09-19 | Improvement in fountain-pen holders and nibs | ||
US5071A (en) | 1847-04-17 | George page | ||
US743A (en) | 1838-05-17 | Improvement in plows | ||
US5932A (en) | 1848-11-21 | brown | ||
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1993001282A1 (en) | 1991-07-01 | 1993-01-21 | Berlex Laboratories, Inc. | Novel mutagenesis methods and compositions |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
US6242222B1 (en) | 1996-06-07 | 2001-06-05 | Massachusetts Institute Of Technology | Programmed sequential mutagenesis |
US5780270A (en) | 1996-07-17 | 1998-07-14 | Promega Corporation | Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP4134378A1 (en) | 2014-11-14 | 2023-02-15 | Regeneron Pharmaceuticals, Inc. | Method for generating high affinity antibodies |
CN113766928A (zh) | 2020-04-02 | 2021-12-07 | 瑞泽恩制药公司 | 抗sars-cov-2纤突糖蛋白抗体和抗原结合片段 |
-
2022
- 2022-07-01 MX MX2024000321A patent/MX2024000321A/es unknown
- 2022-07-01 KR KR1020247003603A patent/KR20240042267A/ko unknown
- 2022-07-01 JP JP2024500049A patent/JP2024527344A/ja active Pending
- 2022-07-01 CN CN202280058249.0A patent/CN118076631A/zh active Pending
- 2022-07-01 WO PCT/US2022/035968 patent/WO2023283134A1/en active Application Filing
- 2022-07-01 IL IL309730A patent/IL309730A/en unknown
- 2022-07-01 EP EP22751504.6A patent/EP4367134A1/en active Pending
- 2022-07-01 CA CA3226042A patent/CA3226042A1/en active Pending
- 2022-07-01 AU AU2022307659A patent/AU2022307659A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL309730A (en) | 2024-02-01 |
EP4367134A1 (en) | 2024-05-15 |
JP2024527344A (ja) | 2024-07-24 |
WO2023283134A1 (en) | 2023-01-12 |
CA3226042A1 (en) | 2023-01-12 |
AU2022307659A1 (en) | 2024-01-25 |
KR20240042267A (ko) | 2024-04-01 |
CN118076631A (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tan et al. | Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques | |
NO20072253L (no) | Forbedrede vaksiner | |
AU2019293244A8 (en) | Personalized cancer vaccine epitope selection | |
MX350230B (es) | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. | |
AR075851A1 (es) | Vacunas anti-cancer dirigidas contra celulas presentadoras de antigenos | |
MX2012003058A (es) | Vacunas dirigidas a celulas de langerhans. | |
UA114502C2 (uk) | Вакцина mycoplasma hyopneumoniae | |
MY155377A (en) | Hiv vaccine based on targeting maximized gag and nef to dendritic cells | |
BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
WO2013177214A3 (en) | Epitope focusing by variable effective antigen surface concentration | |
Gaspar et al. | Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines | |
RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
MX2021013657A (es) | Conjugados de anticuerpo y farmaco. | |
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
WO2018182983A9 (en) | NOROVIRUS PARTICLE S VACCINES AND METHODS OF MAKING AND USING SAME | |
WO2016130560A3 (en) | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats | |
MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
Motozono et al. | The SARS-CoV-2 Omicron BA. 1 spike G446S mutation potentiates antiviral T-cell recognition | |
Sliepen et al. | Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers | |
EA201400914A1 (ru) | Ротавирусная субъединичная вакцина и способы ее получения и применения |